# Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/rituximab-is-preferable-to-cyclophosphamide-for-treatment-of-membranous/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Néstor Oliva-Dámaso,Andrew S. Bomback |
| Citations | 11 |
| DOI | 10.34067/kid.0001842021 |
| Fields | Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | https://kidney360.asnjournals.org/content/kidney360/2/11/1696.full.pdf |
| OpenAlex ID | https://openalex.org/W3155913424 |
| PMID | 35373001 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Néstor Oliva-Dámaso](https://scholariq.org/researchers/nestor-oliva-damaso/)

## Paper journal

- [Kidney360](https://scholariq.org/journals/kidney360/)

## Paper primary topic

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Paper topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.